Azenta, Inc.

Equities

AZTA

US1143401024

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:01:35 2024-04-19 pm EDT 5-day change 1st Jan Change
50.42 USD -0.13% Intraday chart for Azenta, Inc. -8.20% -22.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Azenta, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM
Evercore ISI Raises Azenta's Price Target to $60 From $64, Maintains In Line Rating MT
Jefferies Initiates Coverage on Azenta With Hold Rating, $64 Price Target MT
Azenta Seeks Tuck-In M&A CI
Transcript : Azenta, Inc. Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-19-2024 12:45 PM
Nvidia's dizzying rally spurs rush into AI-themed ETFs RE
Transcript : Azenta, Inc. - Analyst/Investor Day
Needham Trims Price Target on Azenta to $75 From $76, Maintains Buy Rating MT
Azenta's Fiscal Q1 Non-GAAP Earnings, Revenue Decline MT
Transcript : Azenta, Inc., Q1 2024 Earnings Call, Feb 07, 2024
Azenta, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Earnings Flash (AZTA) AZENTA Posts Q1 EPS $0.02, vs. Street Est of $-0.03 MT
Earnings Flash (AZTA) AZENTA Reports Q1 Revenue $154.3M, vs. Street Est of $151.2M MT
Azenta, Inc. Announces the Launch of the BioArc Ultra CI
Azenta, Inc. Announces Election of Directors CI
B. Riley Adjusts Azenta's Price Target to $79 From $61 Ahead of Fiscal Q1 Results Announcement, Keeps Buy Rating MT
Needham Adjusts Azenta's Price Target to $76 From $68, Keeps Buy Rating MT
Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Transcript : Azenta, Inc. Presents at 26th Annual Needham Growth Virtual Conference, Jan-18-2024 10:15 AM
Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc CI
Transcript : Azenta, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM
Tranche Update on Azenta, Inc.'s Equity Buyback Plan announced on November 14, 2022. CI
Transcript : Azenta, Inc. Presents at Stephens Annual Investment Conference | NASH 2023, Nov-16-2023 11:00 AM
Sector Update: Health Care Stocks Higher Late Afternoon MT
Sector Update: Health Care Stocks Advancing in Afternoon Trading MT
Chart Azenta, Inc.
More charts
Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company’s segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
50.49 USD
Average target price
69.6 USD
Spread / Average Target
+37.85%
Consensus
  1. Stock Market
  2. Equities
  3. AZTA Stock
  4. News Azenta, Inc.
  5. Earnings Flash (AZTA) AZENTA Posts Q1 EPS $0.12, vs. Street Est of $0.08